Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palosuran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R known ✓ | Q9UKP6 | 19/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palosuran SCHEMBL29441424 | 1.00 | UTS2R (1.00) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Palosuran SCHEMBL5265025 | 0.96 | UTS2R (1.00) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Palosuran SCHEMBL29441419 | 0.96 | UTS2R (1.00) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Palosuran SCHEMBL1363165 | 0.96 | UTS2R (0.98) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Palosuran SCHEMBL1364002 | 0.96 | UTS2R (0.98) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Palosuran SCHEMBL1364658 | 0.96 | UTS2R (0.98) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4856925 | 0.95 | UTS2R (0.90) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Palosuran SCHEMBL5935080 | 0.93 | UTS2R (0.86) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| Palosuran SCHEMBL5935042 | 0.92 | UTS2R (0.84) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL28753630 | 0.91 | UTS2R (0.83) | UTS2RADRA2ADRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110755434-B | Application of compound palosuran in prevention and treatment of diseases such as skeletal muscle atrophy | 中国医学科学院药物研究所 | 2022-03-15 | — | — | CN | claimed |
| US-8067601-B2 | 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt | Actelion Pharmaceticals Ltd. (CH) | 2011-11-29 | — | — | US | claimed |
| US-20090023775-A1 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1 -YL )-ETHYL]-3-(2-METHYL-QUINOLIN- 4-YL)- UREA AS CRYSTALLINE SULFATE SALT | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-22 | — | — | US | claimed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | claimed |
| EP-1802604-A1 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1-YL)-ETHYL]-3-(2-METHYL-QUINOLIN-4-YL)-UREA AS CRYSTALLINE SULFATE SALT | Actelion Pharmaceuticals Ltd. (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040728-A1 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1-YL)-ETHYL]-3-(2-METHYL-QUINOLIN-4-YL)-UREA AS CRYSTALLINE SULFATE SALT | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-20 | — | — | WO | claimed |
| US-20060079552-A1 | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-04-13 | — | — | US | claimed |
| EP-1499607-B1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-07 | — | — | EP | claimed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | claimed |
| EP-1499607-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-01-26 | — | — | EP | claimed |
| WO-2003048154-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO) -QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-06-12 | — | — | WO | claimed |
| CN-119015282-A | Application of methylquinoline urea compound in preventing and treating malignant tumor cachexia | 中国医学科学院药物研究所 | 2024-11-26 | — | — | CN | disclosed |
| CN-116139127-B | Application of amide compound in preparation of medicament for preventing or treating metabolic syndrome | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | disclosed |
| CN-116115598-B | Application of isoflavone alcohol compound in preparation of medicament for preventing or treating metabolic syndrome | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | disclosed |
| CN-117298111-A | Application of amide compound in preparation of medicament for treating osteoporosis | 中国医学科学院药物研究所 | 2023-12-29 | — | — | CN | disclosed |
| US-20060079552-A1 | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-04-13 | — | — | US | disclosed |
| US-20060079552-A1 | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-04-13 | — | — | US | disclosed |
| EP-1499607-B1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-07 | — | — | EP | disclosed |
| CN-1617869-A | 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-18 | — | — | CN | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023775-A1 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1 -YL )-ETHYL]-3-(2-METHYL-QUINOLIN- 4-YL)- UREA AS CRYSTALLINE SULFATE SALT | REN, SIGMAR1, UTS2R | UTS2R 3/4885ADRA2A 441/4885DRD2 289/4885 |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | UTS2R 1/4885ADRA2A 58/4885DRD2 358/4885 |
| US-20060079552-A1 | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt | REN, AQP1, AQP4 | UTS2R 4/4885ADRA2A 196/4885DRD2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.